IRIS

Chlorine dioxide

CASRN 10049-04-4

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (25 pp, 177 K) last updated: 10/12/2000

System RfD (mg/kg-day) Basis PoD Composite UF Confidence
Nervous, Developmental 3 x 10-2 Neurodevelopmental effects NOAEL : 3
mg/kg-day
100 Medium/High

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (25 pp, 177 K) last updated: 10/12/2000

System RfC (mg/m3) Basis PoD Composite UF Confidence
Respiratory, Cardiovascular 2 x 10-4 Vascular congestion and peribronchial edema LOAEL (HEC): 6.4 x 10-1
mg/m3
3000 Low
Respiratory, Cardiovascular 2 x 10-4 Vascular congestion and peribronchial edema LOAEL (HEC): 6.4 x 10-1
mg/m3
3000 Low

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (25 pp, 177 K) last updated: 10/12/2000

WOE Characterization Framework for WOE Characterization
D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Carcinogenic potential cannot be determined Proposed Guidelines for Carcinogen Risk Assessment (US EPA, 1996)
Basis:
  • Under the current guidelines (U.S. EPA, 1986), chlorine dioxide is classified as Group D; not classifiable as to human carcinogenicity because of inadequate data in humans and animals. Under the draft Carcinogen Assessment Guidelines (U.S. EPA, 1996), the human carcinogenicity of chlorine dioxide cannot be determined because no satisfactory human or animal studies assessing the chronic carcinogenic potential of chlorine dioxide have been located.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (25 pp, 177 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (25 pp, 177 K)

Not assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.